Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

In conclusion, we have demonstrated 1) the feasibility of producing CAR-modified MILs, 2) that CAR-MILs retain their inherent tumor antigen-specificity and functional capacity - something that was lacking with CAR-PBLs, and 3) that CAR-MILs kill more efficiently in vitro than matched CAR-PBLs. These data suggest that CAR-MILs may provide both better antigen specific killing but more importantly by targeting the endogenous antigenic repertoire, they could also prevent or minimize the risk of relapse via antigen escape variants and thus increase the overall efficacy of adoptive CAR T cell therapy.DisclosuresLutz: WIndMIL Therapeutics: Employment, Patents & Royalties. Rudraraju: WIndMIL Therapeutics: Employment. DeOliveira: WIndMIL Therapeutics: Employment. Jana: WIndMIL Therapeutics: Employment. Weiss: WIndMIL Therapeutics: Employment. Borrello: WIndMIL Therapeutics: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding. Noonan: WIndMIL Therapeutics: Employment, Equity Ownership, Patents & Royalties.

Source: Blood - November 21, 2018 Category: Hematology Authors: Lutz, E. R., Hoyos, V., Rudraraju, L., DeOliveira, E., Jana, S., Weiss, I., Borrello, I. M., Noonan, K. Tags: 703. Adoptive Immunotherapy: Poster II Source Type: research